{
    "clinical_study": {
        "@rank": "5114", 
        "brief_summary": {
            "textblock": "This is a double-blind, placebo-controlled, randomized study lasting 8 weeks.  Purpose of\n      the study is two-fold: first, to use a pharmacological agent to treat symptoms of PTSD, and\n      second, to explore neurobiological mechanisms of action of guanfacine."
        }, 
        "brief_title": "Guanfacine for the Treatment of Post Traumatic Stress Disorder (PTSD)", 
        "completion_date": "October 2002", 
        "condition": "Post-Traumatic Stress Disorder", 
        "condition_browse": {
            "mesh_term": [
                "Stress Disorders, Post-Traumatic", 
                "Stress Disorders, Traumatic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Subject population is comprised of 100 persons with PTSD.  50 patients will receive\n      guanfacine and 50 patients will receive a placebo.  Guanfacine is prescribed at 1 mg/day and\n      may be increased to 2 mg/day.  Samples of plasma MHPG will be collected weekly.  Clinical\n      ratings of PTSD anxiety and depression, as well as vital signs, will be assessed weekly.\n      Repeated measures analysis of variance will assess significance of main effect of drug,\n      time, and drug by time."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "-  Males and females, age 18-65\n\n          -  Diagnosis of PTSD from combat or civilian trauma\n\n          -  No major medical problems such as diabetes, cardiovascular disease\n\n          -  Taking no psychiatric medication, or taking only one SSRI antidepressant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "July 3, 2001", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00018603", 
            "org_study_id": "MHBS-047-99F"
        }, 
        "intervention": {
            "intervention_name": "guanfacine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Guanfacine"
        }, 
        "keyword": "PTSD", 
        "lastchanged_date": "January 20, 2009", 
        "location": {
            "facility": {
                "address": {
                    "city": "West Haven", 
                    "country": "United States", 
                    "state": "Connecticut", 
                    "zip": "06516"
                }, 
                "name": "VA Connecticut Healthcare System"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Guanfacine for the Treatment of PTSD", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00018603"
        }, 
        "source": "Department of Veterans Affairs", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Department of Veterans Affairs", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "November 1999", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2004"
    }, 
    "geocoordinates": {
        "VA Connecticut Healthcare System": "41.271 -72.947"
    }
}